Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2022 ∙ Yin, J. Chen, Y. Li, Y. Wang, C. Zhang, X.

Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis

  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Manothummetha, K. Chuleerarux, N. Sanguankeo, A. Kates, O. S. Hirankarn, N. Thongkam, A. Dioverti-Prono, M. V. Torvorapanit, P. Langsiri, N. Worasilchai, N. Moonla, C. Plongla, R. Garneau, W. M. Chindamporn, A. Nissaisorakarn, P. Thaniyavarn, T. Nematollahi, S. Permpalung, N.

Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2022 ∙ Becerril-Gaitan, A. Vaca-Cartagena, B. F. Ferrigno, A. S. Mesa-Chavez, F. Barrientos-Gutierrez, T. Tagliamento, M. Lambertini, M. Villarreal-Garza, C.

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

  • Adults
  • Adolescents
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Uaprasert, N. Pitakkitnukun, P. Tangcheewinsirikul, N. Chiasakul, T. Rojnuckarin, P.

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

  • Adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Kang, L. Shang, W. Gao, P. Wang, Y. Liu, J. Liu, M.

Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Ma, B. M. Tam, A. R. Chan, K. W. Ma, M. K. M. Hung, I. F. N. Yap, D. Y. H. Chan, T. M.

Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Lv, J. Wu, H. Xu, J. Liu, J.

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Cheng, H. Peng, Z. Si, S. Alifu, X. Zhou, H. Chi, P. Zhuang, Y. Mo, M. Yu, Y.

Immunogenicity and Safety of Homologous and Heterologous Prime-Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis

  • Adults
  • Older adults
  • Healthcare workers
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Peiyao, R. Mengjie, Y. Xiaogang, S. Wenfang, H. Danna, Z. Yuqun, Z. Juan, J. Qiang, H.

Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Falahi, S. Sayyadi, H. Kenarkoohi, A.

Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis

  • All age groups
  • Healthcare workers
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
Loading...